melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
== Random versus site-directed == Numerous enzymes of biotechnological importance have been immobilized on various supports (inorganic, organic, composite and nanomaterials) via random multipoint attachment. However, immobilization via random chemical modification results in a heterogeneous protein population where more than one side chains (amino, carboxyl, thiol etc) present in proteins are linked with the support with potential reduction in activity due to restriction of substrate access to the active site. In contrast, in site-directed enzyme immobilization, the support can be linked to a single specific amino acid (generally N- or C-termini) in a protein molecule away from the active-site. This way maximal enzyme activity is retained due to the free access of the substrate to the active-site. These strategies are mainly chemical but may additionally require genetic and enzymatic methods to generate functional groups (that are absent in protein) on the support and enzyme. The choice of SDCM method depends on many factors, such as the type of enzyme (less stable psychrophilic, or more stable thermophilic homologue), pH stability of enzyme, the availability of N- or C-termini to the reagent, non-interference of the enzyme terminus with the enzyme activity, type of catalytic amino acid residue, the availability, price and the ease of preparation of reagents. For example, the generation of complementary clickable functionalities (alkyne and azide) on the support and enzyme is one of the most convenient way for immobilizing enzymes via site-directed chemical modification.
As of 2018, the treaty has been signed by 166 countries, by signing states agreed to take steps to the maximum of their available resources to achieve the right to adequate food. However, after the 1966 International Covenant the global concern for the access to sufficient food only became more present, leading to the first ever World Food Conference that was held in 1974 in Rome, Italy. The Universal Declaration on the Eradication of Hunger and Malnutrition was a UN resolution adopted November 16, 1974, by all 135 countries that attended the 1974 World Food Conference. This non-legally binding document set forth certain aspirations for countries to follow to sufficiently take action on the global food problem. Ultimately this document outline and provided guidance as to how the international community as one could work towards fighting and solving the growing global issue of malnutrition and hunger. Adoption of the right to food was included in the Additional Protocol to the American Convention on Human Rights in the area of Economic, Social, and Cultural Rights, this 1978 document was adopted by many countries in the Americas, the purpose of the document is, "to consolidate in this hemisphere, within the framework of democratic institutions, a system of personal liberty and social justice based on respect for the essential rights of man." A later document in the timeline of global initiatives for malnutrition was the 1996 Rome Declaration on World Food Security, organized by the Food and Agriculture Organization.
1-hydroxy-2-naphthoate hydroxylase (EC 1.14.13.135, 1-hydroxy-2-naphthoic acid hydroxylase) is an enzyme with systematic name 1-hydroxy-2-naphthoate,NAD(P)H:oxygen oxidoreductase (2-hydroxylating, decarboxylating). This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
=== Plutonium research === LLNL conducts research into the properties and behavior of plutonium to learn how plutonium performs as it ages and how it behaves under high pressure (e.g., with the impact of high explosives). Plutonium has seven temperature-dependent solid allotropes. Each possesses a different density and crystal structure. Alloys of plutonium are even more complex; multiple phases can be present in a sample at any given time. Experiments are conducted at LLNL and elsewhere to measure the structural, electrical and chemical properties of plutonium and its alloys and to determine how these materials change over time. Such measurements enable scientists to better model and predict plutonium's long-term behavior in the aging stockpile. The Lab's plutonium research is conducted in a specially designed facility called the SuperBlock, with emphasis on safety and security. Work with highly enriched uranium is also conducted there. In March 2008, the National Nuclear Security Administration (NNSA) presented its preferred alternative for the transformation of the nation's nuclear weapons complex. Under this plan, LLNL would be a center of excellence for nuclear design and engineering, a center of excellence for high explosive research and development, and a science magnet in high-energy-density (i.e., laser) physics. In addition, most of its special nuclear material would be removed and consolidated at a more central, yet-to-be-named site.
The game's production was turbulent, as the design's scope exceeded the available resources, and the team was left without a producer for nearly a year until Activision appointed David Mullich to the role, where he found designs and levels unfinished or abandoned. After three years in development with no end in sight and running over budget, Activision set a strict deadline for completion, and Bloodlines was released incomplete in November 2004. Released in competition with Half-Life 2 and several other titles, Bloodlines sold fewer than 80,000 copies during its initial release, which was considered a poor performance. It received generally positive reviews from contemporary critics, who praised the game's writing and the scale of choice, although they criticized its technical flaws. It was Troika Games's last production before its failure in early 2005, when it could not secure additional projects. The game has a cult following as a rarely replicated example of gameplay and narrative, and modern reception recognizes it as a flawed masterpiece. Since its original release, Bloodlines received post-release support from fans, supplying unofficial fixes and re-adding unused content. A sequel, Vampire: The Masquerade – Bloodlines 2, was released in 2025.
The iron storage disorder hereditary hemochromatosis (HHC) is an autosomal recessive genetic disorder that usually results from defects in this gene. The disease-causing genetic variant most commonly associated with hemochromatosis is p. C282Y. About 1/200 of people of Northern European origin have two copies of this variant; they, particularly males, are at high risk of developing hemochromatosis. This variant may also be one of the factors modifying Wilson's disease phenotype, making the symptoms of the disease appear earlier. Allele frequencies of HFE C282Y in ethnically diverse western European white populations are 5-14% and in North American non-Hispanic whites are 6-7%. C282Y exists as a polymorphism only in Western European white and derivative populations, although C282Y may have arisen independently in non-whites outside Europe. HFE H63D is cosmopolitan but occurs with greatest frequency in individuals of European descent. Allele frequencies of H63D in ethnically diverse western European populations are 10-29%. and in North American non-Hispanic whites are 14-15%. At least 42 mutations involving HFE introns and exons have been discovered, most of them in persons with hemochromatosis or their family members. Most of these mutations are rare. Many of the mutations cause or probably cause hemochromatosis phenotypes, often in compound heterozygosity with HFE C282Y. Other mutations are either synonymous or their effect on iron phenotypes, if any, has not been demonstrated.
Sources: en.wikipedia.org
Evelyn Greechan, Senior Traffic Warden, City of Glasgow Police. For services to Road Safety. Ian Greenlaw, Support Grade Band 1, Her Majesty's Customs and Excise. Brian Gregory, Facilities Manager, Sussex Police. For services to the Police. Sylvia Gladys Grove, Office Support Grade Band 2, Home Office. Alan Joseph Gruar, Training Manager, Lucas Aerospace, Wolverhampton Training Centre, LucasVarity plc. For services to Training. Leslie Gurney. For services to the community in Stockport, Cheshire. Jessie Haggarty. For services to Highland Dancing. Jonathan Ian Hague, Detective Inspector, Metropolitan Police. For services to the Police. Alfred Hall. For services to the World Ploughing Organisation. Arthur Charles Hall. For services to the community in Walton-on-Thames, Surrey. Eileen Hall, Administrative Officer, Department of Social Security. Edna Hilda Knight Hallatt, Governor, Newcastle-under-Lyme School, Staffordshire. For services to Education. Mae Hamilton, Administrative Officer, Home Office. Brenda Margaret Hancock, lately Personal Secretary, Health and Safety Executive, Department of the Environment Angela Kathenne Hanley, Training Manager, First Aid Centre, London Transport. For services to Public Transport. Hilda Harding. For services to Mind and to the Elderly and Disadvantaged in Sutton, Surrey. Anthony Shannon Harman. For services to Agriculture and to the British Charolais Cattle Society. Susan Gladys Harper, Practice Nurse (Sister), Roslin Medical Centre, Midlothian. For services to Health Care. David Harris.
== Political organization == Lad served as General Secretary of the Karnataka Pradesh Congress Committee (KPCC) and was given responsibility for Raichur district organization during his earlier period in Congress politics. In January 2023, the Congress appointed Lad as a co-chairman in the party's Karnataka Assembly election campaign committee, with responsibility for the Belagavi division. He also participated in Congress's Bharat Jodo Yatra activities in Karnataka in 2022. Lad started his political career as a counsellor from Sandur taluk. He had very little success in Pattana panchayat elections, where he lost marginally in his first election. He went on to win both seats he contested in the following election, contributing to his party gaining the majority during that period. Lad contested the MLA election against a strong contender from the Congress Party. He represented the Janata Dal (Secular) party and was the youngest MLA (aged 29), along with the first person from his party to win Sandur constituency; the election was won with a record margin. Lad was part of the government formation under H. D. Kumaraswamy, ex-chief minister of the Karnataka state. In the 2008 Karnataka Assembly elections, he won the Kalaghatgi constituency in the Dharwad district. He currently is an active member and represents Indian National Congress. In the 2013 Karnataka state assembly election, Santosh Lad won with a margin of over 45,000 votes, to win consecutively for the second time from Kalaghatgi and third time overall. Congress secured an absolute majority to form the government.
Chemiosmosis is the movement of ions across a semipermeable membrane through an integral membrane protein, down their electrochemical gradient. An important example is the formation of adenosine triphosphate (ATP) by the movement of hydrogen ions (H+) through ATP synthase during cellular respiration or photophosphorylation.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.